Telos Capital Management Inc. Sells 90 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Telos Capital Management Inc. lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 0.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,836 shares of the pharmaceutical company’s stock after selling 90 shares during the quarter. Telos Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $5,159,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Csenge Advisory Group boosted its stake in Vertex Pharmaceuticals by 5.8% in the third quarter. Csenge Advisory Group now owns 2,067 shares of the pharmaceutical company’s stock worth $719,000 after buying an additional 114 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Vertex Pharmaceuticals by 17.9% in the third quarter. Daiwa Securities Group Inc. now owns 36,636 shares of the pharmaceutical company’s stock worth $12,739,000 after buying an additional 5,572 shares in the last quarter. AIA Group Ltd boosted its stake in Vertex Pharmaceuticals by 1.9% in the third quarter. AIA Group Ltd now owns 17,088 shares of the pharmaceutical company’s stock worth $5,942,000 after buying an additional 314 shares in the last quarter. Vanguard Capital Wealth Advisors boosted its stake in Vertex Pharmaceuticals by 21.6% in the third quarter. Vanguard Capital Wealth Advisors now owns 1,070 shares of the pharmaceutical company’s stock worth $372,000 after buying an additional 190 shares in the last quarter. Finally, New Mexico Educational Retirement Board boosted its stake in Vertex Pharmaceuticals by 7.2% in the third quarter. New Mexico Educational Retirement Board now owns 13,400 shares of the pharmaceutical company’s stock worth $4,660,000 after buying an additional 900 shares in the last quarter. Institutional investors own 90.77% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $415.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 9th. StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th. Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $359.00 to $364.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. BMO Capital Markets increased their price objective on Vertex Pharmaceuticals from $389.00 to $415.00 and gave the company an “outperform” rating in a research note on Tuesday, November 7th. Finally, Truist Financial reissued a “buy” rating and set a $456.00 price objective on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 4th. Six investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $381.86.

Check Out Our Latest Report on VRTX

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $433.76 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $283.60 and a 1-year high of $439.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.08 and a quick ratio of 3.89. The business has a fifty day moving average price of $386.04 and a 200-day moving average price of $365.43. The company has a market capitalization of $111.77 billion, a PE ratio of 32.54, a PEG ratio of 2.80 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its quarterly earnings results on Monday, November 6th. The pharmaceutical company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.53 by $0.55. Vertex Pharmaceuticals had a return on equity of 22.79% and a net margin of 35.94%. The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the company earned $3.62 earnings per share. The company’s revenue was up 6.4% on a year-over-year basis. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 13.73 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs sold 11,250 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $385.00, for a total transaction of $4,331,250.00. Following the sale, the director now directly owns 40,000 shares of the company’s stock, valued at $15,400,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 11,250 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $385.00, for a total value of $4,331,250.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $15,400,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Carmen Bozic sold 5,651 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $355.92, for a total value of $2,011,303.92. Following the completion of the transaction, the chief marketing officer now directly owns 34,952 shares in the company, valued at $12,440,115.84. The disclosure for this sale can be found here. Insiders have sold 23,549 shares of company stock valued at $9,128,531 over the last ninety days. Insiders own 0.40% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.

Featured Stories

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.